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The thyroperoxidase (TPO) enzyme is expressed by the thyroid follicular cells and is required for thyroid
hormone synthesis. In turn, thyroid hormones are essential for brain development, thus inhibition of TPO
in early life can have life-long consequences for brain function. If environmental chemicals with the
capacity to inhibit TPO in vitro can also alter brain development in vivo through thyroid hormone
dependent mechanisms, however, remains unknown. In this study we show that the in vitro TPO
inhibiting pesticide amitrole alters neuronal migration and induces periventricular heterotopia; a thyroid
hormone dependent brain malformation. Perinatal exposure to amitrole reduced pup serum thyroxine
(T4) concentrations to less than 50% of control animals and this insufficiency led to heterotopia formation
in the 16-day old pup’s brain. Two other in vitro TPO inhibitors, 2-mercaptobenzimidazole and cyana-
mide, caused reproductive toxicity and had only minor sporadic effects on the thyroid hormone system;
consequently, they did not cause heterotopia. This is the first demonstration of an environmental
chemical causing heterotopia, a brain malformation until now only reported for rodent studies with the
anti-thyroid drugs propylthiouracil and methimazole. Our results highlight that certain TPO-inhibiting
environmental chemicals can alter brain development through thyroid hormone dependent mecha-
nisms. Improved understanding of the effects on the brain as well as the conditions under which
chemicals can perturb brain development will be key to protect human health.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Proper brain development is critically dependent on thyroid
hormones. Epidemiological studies show associations between low
maternal thyroxine (T4) concentrations and neurodevelopmental
effects manifesting as decreased intelligence coefficients (IQ) and
cognitive disorders later in the child’s life (Andersen et al., 2018;
Fetene et al., 2017; Ghassabian et al., 2014; Gyllenberg et al., 2016;
Haddow et al., 1999; Korevaar et al., 2016; Roman et al., 2013).e by Wen Chen.
nmark, Kemitorvet, Bygning
r Ltd. This is an open access articleThese associations have been confirmed in animal studies, where
disruption of thyroid hormone signalling during development led
to brainmalformations and behavioural effects in the maturing and
adult offspring (Akaike et al., 1991; Auso et al., 2004; Axelstad et al.,
2008; Gilbert et al., 2016; Gilbert and Sui, 2006; Lavado-Autric
et al., 2003; Richard et al., 2020; Sharlin et al., 2008). Thus, it is
reasonable to assume that exposures in early life to environmental
chemicals that can disrupt the thyroid hormone system can also
perturb brain development and ultimately pose a threat to human
health.
The thyroid hormone system comprises a complex network of
hormones, transporters, metabolizing enzymes and receptors, with
tissues and organs interconnected by regulatory feedback loops.
This means that environmental chemicals can disrupt the thyroidunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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established mechanism, and the focus of this study, is inhibition of
the thyroperoxidase (TPO) enzyme (Crofton et al., 2019; Hassan
et al., 2017). TPO is exclusively expressed in the thyroid gland
where it functions to synthesise thyroid hormones. TPO oxidizes
iodide to iodine, iodininates thyroglobulin and couples iodinated
tyrosine residues to form the thyroid hormone iodothyronines T4
and 3,30,5-tri-iodothyronine (T3) (Carvalho and Dupuy, 2017). Since
thyroid hormones cannot be synthesized without properly func-
tioning TPO, inhibition of this enzyme can severely diminish serum
T4 concentrations. This critical role is exploited in medical treat-
ment of hyperthyroidism, where the antithyroid drugs propylth-
iouracil (PTU) and methimazol (MMI) reduce serum T4
concentrations by inhibiting TPO activity. When given to pregnant
and lactating rats, both PTU and MMI markedly reduce serum T4
concentrations in dams, foetuses and pups throughout develop-
ment (Hasebe et al., 2008; Hassan et al., 2017; Morreale de Escobar
et al., 1988; O’Shaughnessy et al., 2018b; Ruiz de O~na et al., 1988).
The suppression of thyroid hormone production during devel-
opment by PTU and MMI can have severe consequences for
neurological development in the offspring. One of the effects on the
developing brain is disrupted neuronal migration, resulting in a
type of irreversible brain damage, periventricular heterotopia,
which are misplaced neurons found in the white matter of the
pup’s brains (Gilbert et al., 2014; Goodman and Gilbert, 2007;
O’Shaughnessy et al., 2018a, 2019; Shibutani et al., 2009; Shiraki
et al., 2012; Spring et al., 2016). These misplaced neurons cluster
closely in the corpus callosum to form heterotopia whose size in-
creases with increasing T4 deficiency while their formation can be
prevented by co-administration of T4 (Gilbert et al., 2014;
Goodman and Gilbert, 2007; O’Shaughnessy et al., 2019). Hetero-
topia can be detected in rodent brains even after exposure to doses
of PTU that only have minor effects on maternal serum T4 con-
centrations, but concomitantly severely reduce foetal and neonatal
thyroid hormone concentrations in serum and brain (Gilbert et al.,
2014; Hassan et al., 2017; O’Shaughnessy et al., 2018b, 2019). The
reduced T4 concentrations in neonatal brains after PTU adminis-
tration may well explain the ability of the drug to produce heter-
otopia. However, PTU and MMI are highly potent drugs designed to
suppress T4. Whether or not heterotopia may develop from expo-
sure to environmental chemicals designed for other purposes, but
then also found to inhibit TPO in vitro, remains unknown (Gilbert
et al., 2020).
To test if TPO inhibitors can cause heterotopia in the brain, weFig. 1. Work flow for systematic prioritization strategy of thyroperoxidase (TPO) inhibito
93 potent inhibitors of TPO that were not toluene or aniline derivatives there were no availab
there were data showing investigated thyroid gland endpoints unaffected. The remaining 20
compounds were chosen for this study. REACH: Registration, Evaluation, Authorisation and
2
leveraged information from the U.S. Environmental Protection
Agency’s (EPA’s) Toxicity Forecaster (ToxCast) which has identified
a host of chemicals that can inhibit TPO in in vitro assays (Friedman
et al., 2016; US EPA, 2020). Our aim was to establish whether
environmental chemicals that are in vitroTPO inhibitors can disrupt
the thyroid hormone system to such an extent that brain devel-
opment is severely disrupted and heterotopia are formed. Such
studies are urgently needed to identify hazards for brain develop-
ment that may be associated with in vitro TPO inhibition.
2. Materials and methods
2.1. Test chemicals
We applied a systematic selection process using Toxcast, pub-
lished literature and the REACH registration database to identify
three TPO inhibitors for developmental toxicity screening in vivo
(see Fig. 1 and 3.1). We chose compounds that were potent TPO
inhibitors in vitro, showed clear evidence of thyrotoxic potential
in vivo, and had a presumed lack of carcinogenicity and neurotox-
icity through modes of action other than TPO inhibition. Further-
more, some published toxicity studies with pregnant animals
needed to be available to allow for dose selection to avoid doses
causing overt maternal toxicity. Lastly, we excluded well estab-
lished goitrogens that were considered positive controls for TPO
inhibition. Based on this procedure, we selected the following
compounds for in vivo testing: 2-Mercaptobenzimidazole (MBI)
(CAS no: 583-39-1, Sigma-AldrichM3205-5G, lot: STBH8752, purity
98%), 3-Amino-1H-1,2,4-triazole (amitrole) (CAS no: 61-82-5,
Sigma-Aldrich 8144950100, batch: S7075495 847, purity >97.0%)
and cyanamide (CAS no: 420-04-2, Sigma-Aldrich, 187,364-5G, lot:
STBH8303, purity 99%).
2.2. Animals and treatments
Time-mated nulliparous Sprague-Dawley rats (Crl:CD(SD) bred
by Charles River Europe, distributed by SCANBUR, Denmark) with a
body weight of approximately 240 ± 30 g were received at gesta-
tion day (GD) 3 of pregnancy (the day of plug detection designated
as GD1). On GD4 the 28 dams were weighed, randomized and
assigned to 7 dose groups with similar weight distributions (n ¼ 4
per group). The exposure groups were: a vehicle control group, and
two doses each of MBI (10 and 20 mg/kg bw/day), amitrole (25 and
50 mg/kg bw/day) and cyanamide (7 and 15/11.25 mg/kg bw/day).rs for in vivo testing for heterotopia linked to thyroid hormone insufficiency. Out of
le in vivo data on thyroid effects for more than 50% of the compounds. For another ~25%
compounds were investigated for their suitability for developmental studies. Finally, 3
Restriction of Chemicals, TPO: Thyroperoxidase, IC: Inhibitory concentration.
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of 15 mg/kg cyanamide was lowered to 11.25 mg/kg from GD16
onwards. All dams were dosed daily, in the morning, by oral gavage
and with a constant volume of 2 ml/kg bw. Dosing began at GD7
and lasted to postnatal day (PD) 22, except the day of birth. Corn oil
(Sigma-Aldrich) was used as a vehicle and in the control group.
The dams were housed pairwise within treatment groups until
GD17, and individually thereafter. The animals were housed in
semi-transparent polysulfone (PSU) type III cages (PSU 80-
1291HOOSU Type III, Tecniplast S.p.A, Buguggiate, Italy)
(15  27  43 cm). Aspen wood chip bedding (Tapvei, Gentofte,
Denmark), Enviro Dri nesting material (Brogaarden, Lynge,
Denmark), and Tapvei Arcade 17 (aspen wood) shelters (Bro-
gaarden) were provided. Cages were placed in ScanTainers (venti-
lated cabinets, Scanbur) with ScanClime (Scanbur) controlled
environmental conditions: humidity 55 ± 5%, temperature at
21 ± 1 C and airchange 50 times per hour. Reversed light/dark
cycles of 12 h with sunrise/sunset of 30 min (light from 9 p.m. to 9
a.m., dark from 9 a.m. to 9 p.m.). All animals were provided ad
libitum acidified tap water (to prevent microbial growth) in PSU
bottles (84-ACBTO702SU Tecniplast) and were fed ad libitum on a
standard diet with Altromin 1314 (soy and alfalfa-free, Altromin
GmbH, Lage, Germany). The iodine content of this diet was 1.52mg/
kg and the selenium content 0.26 mg/kg.
Dam body weights were recorded daily before dosing and all
animals were inspected twice daily for signs of toxicity. Dams from
the control, amitrole and cyanamide groups all gave birth on GD23
in the morning (assigned as PD1 for all pups). Dams from the
10 mg/kg MBI group all gave birth in the afternoon of GD23 and all
dams in the high dose MBI (20 mg/kg) had to be killed due to
parturition problems (one dam on GD22, the remaining three in the
afternoon on GD23). Thus, the 20 mg/kg group did not deliver any
viable litters and was excluded from most analyses.
On the day of birth (PD1), pups were weighed, sexed and
counted. Pup weights were recorded on PD6, 14 and 22 when the
study was terminated. Onemale and one female pup per litter were
killed by decapitation on PD6. On PD16, three males and two fe-
males were killed by decapitation under CO2/O2 anesthesia, and on
PD22 the same procedure was used to terminate dams and the
remaining pups.
The animal experiments were carried out in the BioFacility of
the Technical University of Denmark. Ethical approval was given by
the Danish Animal Experiments Inspectorate, authorization num-
ber 2015-15-0201-00553 C3. The experiments were overseen by
the in-house Animal Welfare Committee for animal care and use at
the National Food Institute.
2.3. Serum hormone concentrations
Serum samples were collected in Eppendorf tubes without
heparin, on GD15 by tongue bleeding of unanaesthetized dams.
Trunk blood was collected on PD6 (one male and one female pup
per litter) and PD16 (three males pooled and 2 females pooled for
each litter) and dams on PD22. Blood was kept on ice (<1 h) until
centrifugation for 10 min at 4 C and 4000 rotations per minute
(rpm), serum was collected and stored at 80 C until analysis.
Serum total T3 and T4 were determined in duplicates in dams at
GD15 and PD22 and in offspring at PD6 (only T4 due to small vol-
ume) and PD16 using validated radioimmunoassays (RIA4524 resp.
RIA4525; DRG Instruments (Marburg, Germany)). To improve
sensitivity, two additional concentrations were added to the stan-
dard curves by diluting the lowest standard calibrator by a factor of
4 and 8with the zero standard providedwith the assay kit. All other
standard calibrators were diluted by a factor 2 with the zero stan-
dard. Also to improve sensitivity the sample and standard volumes3
were doubled when compared to the manufacturer’s protocol.
According to the manufacturer’s protocol samples and calibrators
for a standard curve were incubated with 125I-T4 or 125I-T3 as a
tracer in antibody-coated tubes for 1 h. Bound radioactivity was
determined in a gamma counter (1277 GammaMaster; LKBWallac,
Turku, Finland). The limit of quantificationwas 4.0 nM and 0.20 nM
for total T4 and T3, respectively. Intra-assay coefficients of variation
were <10% and <8%, respectively.
Serum TSH was measured in GD15 dams and PD16 offspring by
the Milliplex MAP rat pituitary magnetic bead panel (RPTMAG-
86 K; EMDMillipore, Darmstadt, Germany). The TSHMilliplex assay
was performed following the manufacturer’s instructions. The limit
of quantification was 3.2 pg/ml for TSH. Intra-assay coefficients of
variation were <10.5%.
2.4. Organ weights and tissue samples
Necropsy was performed on two male pups per litter on PD16
and on PD22 dams. The pups were weighed, decapitated and thy-
roid gland and liver were excised and weighed. Brain with cere-
bellum (one pup per litter from high dose only) was excised and
immersion fixed in 10% formalin for 5 days. After fixation, the
brains were blocked with coronal cuts anterior and posterior to the
hippocampus. The blocks (containing the hippocampus) were
processed and paraffin embedded. The brains were sectioned at
10 mm and every 3rd section collected. Collection took place from
the anterior hippocampus to the division of the corpus callosum.
On PD22, at termination of the study, the dams were killed, and
thyroid glands and livers removed and weighed. The uteri were
excised and implantation scars counted.
2.5. Immunohistochemistry and detection of heterotopia
Immunohistochemical staining was performed on brain sec-
tions with NeuN antibody in Shandon Sequenza Immunostaining
racks (Thermo Scientific, Roskilde, Denmark). Sections were boiled
in a microwave for 15 min in Tris/EDTA buffer (pH 8.95e9.05) and
blocked in 1% bovine serum albumin in PBS buffer for 30 min.
Sections were incubated overnight at 4 C with 1:15,000 NeuN
(MAB377 Neuronal Nuclei, EMB Millipore Corp, now Merck,
Darmstadt, Germany) in 1% bovine serum albumin. Endogenous
peroxidase was blocked with 3% H2O2 in PBS for 10 min and then
incubated for 30 min with EnVision þ System-HRP Labelled Poly-
mer Anti-mouse (K4001, Dako, Glostrup, Denmark). Sections were
stained in DABþ (Dako, Glostrup, Denmark) for 10 min, and
counterstained in Meyer’s hematoxylin.
Sections were evaluated for heterotopia, as first described by
Goodman and Gilbert (2007), by light microscopy in the corpus
callosum from the midline and more lateral until inferior to the
frontal cortex area 2. A heterotopia was defined as a minimum of 5
large NeuN þ cells in the near vicinity of each other and present on
at least 2 adjacent sections over the subiculum and present on
sections towards the posterior part of the hippocampus. Hemi-
spheres on which a heterotopia was identified were counted and
summed for left and right hemisphere per animal, then averaged
across groups.
2.6. Statistical analysis
Data from continuous endpoints (e.g. hormones, organweights)
were analyzed for dose-related effect differences to the controls by
General Linear Models (GLM), with data from all treatment groups
analyzed in the same model. If deemed necessary, data were log-
transformed prior to data analysis, and covariates were included
in data analysis when considered appropriate (e.g., litter size for
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hormones). Litter effects were accounted for by analysing data from
one pup per litter, by using litter means or for male pup organ
weights (where two pups per litter were included) by using litter as
an independent, random and nested factor in the statistical anal-
ysis. Gestation length, post-implantation loss and perinatal loss
were investigated for differences to the controls by the non-
parametric Kruskal-Wallis test. Statistical testing between control
and treatment groups was Dunnett-adjusted to account for multi-
ple testing (a ¼ 5%, two-sided). Heterotopia formation was
assumed to follow a Poisson distribution (according to unpublished
data), and significant differences between the control and treat-
ment means were investigated by contrast testing in a Poisson
regression model, with p-values adjusted for multiple testing ac-
cording to the Holm-Sidak (Abdi, 2007). All statistical analyses
were conducted in SAS Enterprise v8.3.
3. Results
3.1. Systematic selection of test compounds
We used the ToxCast database as a starting point for selecting
TPO inhibitors for our studies and applied a systematic selection
process (Fig. 1) (US EPA, 2020). A list of the most potent in vitro TPO
inhibitors was extracted from the database (n ¼ 320). Compounds
with IC50 values > 10 mMwere excluded, as were estrogens, aniline
derivatives suspected of carcinogenicity, potentially directly
neurotoxic compounds (organic toluene solvents and organo-
phosphorus pesticides) (n¼ 44) and compoundswithmaximal TPO
inhibition (efficacy) < 60% in the Toxcast assay (n ¼ 38). For the
remaining 90 compounds, we searched for in vivo studies of thyroid
hormone system disrupting effects. According to our searches in
Pubmed (https://pubmed.ncbi.nlm.nih.gov/) and in the REACH
registration database (https://echa.europa.eu/home) more than
50% of the compounds had not been studied for thyroid related
effects in vivo, and these were excluded (n ¼ 49). Also excluded
were compounds that did not show effects on thyroid-related
endpoints (n ¼ 24). Notably, most of these compounds had been
inadequately investigated; “no effect”-data on thyroid histopa-
thology and cancer development were available for most com-
pounds, but effects on thyroid hormone concentrations had only
been investigated for a few of them. Eligibility was determined for
the remaining 17 compounds: for 10 of them, in vivo effects
appeared weak or inconsistent, or there were no developmental
studies available. At the end of this process, we were left with 7
compounds that fitted our selection criteria (Table 1). After
excluding compounds that could be regarded as positive controls
(6-propyl-2-thiouracil, 6-methyl-2-thiouracil, methimazole and
ethylene thiourea) (n ¼ 4), we arrived at 3 suitable test compounds
all in current use in the European Union: 2-MercaptobenzimidazoleTable 1
TPO inhibitory properties, selected test compounds and positive control
compounds.




2-Mercaptobenzimidazole (MBI) 0.06 97% yes
Methimazole (MMI) 0.06 83% e
6-Propyl-2-thiouracil (PTU) 0.23 93% e
6-Methyl-2-thiouracil (MTU) 0.46 95% e
Amitrole 1.76 69% yes
Cyanamide 2.42 86% yes
Ethylene Thiourea (ETU) 7.75 102% e
Data from ToxCast (US EPA, 2020).
a Percent maximal inhibition of thyroperoxidase (TPO).
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(MBI), amitrole and cyanamide. MBI is used as a rubber anti-
oxidant and anti-corrosive agent, amitrole is a herbicide and
biocide, and cyanamide is applied in agriculture as a rest-breaking
agent to stimulate the uniform opening of buds.
3.2. Systemic, reproductive and developmental toxicity
The three compounds chosen for in vivo testing e MBI, amitrole
and cyanamide e produced surprisingly different toxic effect pat-
terns in dams and offspring. Most striking were the effects by MBI,
where dams experienced problems giving birth (dystocia) at the
highest dose (20 mg/kg). As a result, one dam had to be killed on
GD22 and the remaining three on GD23 (Table 2). All the dams that
received the lower dose of 10 mg/kg MBI delivered viable, although
smaller, litters after prolonged gestation (i.e. in the afternoon on
GD23, while animals exposed to control, amitrole and cyanamide
all had delivered by themorning of GD23) (p¼ 0.001). In the 10mg/
kg group there was reduced pup survival with a perinatal loss of
18%. Offspring body weight was lower in MBI treated litters
compared with controls. This effect was statistically significant in
the male offspring on PD16.
Amitrole caused diminished pup growth in the later postnatal
period (Table 2), an effect that potentially can be ascribed to thyroid
hormone insufficiency (see below). Amitrole did not produce ef-
fects on dam body weights or other signs of maternal toxicity.
Lastly, cyanamide reduced dam gestational body weight gains.
After 10 days of treatment it became evident that the highest dose
(15 mg/kg bw/day) caused a marked decrease in body weight gain
in the pregnant dams (33 ± 10 g) compared to control dams
(52 ± 7 g). Consequently, we lowered this high dose to 11.25 mg/
kg bw/day from GD16 onwards. This dose reduction restored body
weight gains from GD16-GD21 to levels similar to those seen with
the lower cyanamide dose (7.5 mg/kg) and with untreated controls
(~63 g in all three groups). However, both doses of cyanamide
produced markedly decreased body weights in the offspring. In
male pups, these decreases reached statistical significance from
PD14 onwards; in female pups this was the case on PD22 (Table 2).
Thus, testing cyanamide at doses exceeding 11.25 mg/kg bw/day
would have produced excessive systemic toxicity in the dams and
offspring.
None of the compounds significantly affected absolute liver
weights (adjusted for body weight in the statistical analysis),
neither in the dams nor the offspring (Table 2).
In summary, MBI induced clear reproductive toxicity, rendering
dams unable to give birth at the high dose (20 mg/kg) and, at the
lower dose of 10 mg/kg, prolonging gestation and causing pup loss.
Cyanamide (15 mg/kg) decreased maternal gestational weight
gains and amitrole, along with the other two compounds,
decreased pup body weights postnatally.
3.3. Maternal thyroid hormone system disruption
After one week of exposure to MBI, amitrole and cyanamide
(GD15), and at study termination (PD22), we measured maternal
thyroid hormone serum concentrations. On GD15 there were no
statistically significant changes to T4, T3 or TSH after exposure to
amitrole and cyanamide. In contrast, MBI reduced serum T3
(p ¼ 0.037) and caused increased TSH concentrations (p ¼ 0.017) in
the high dose group (20 mg/kg), indicating activation of the HPT-
axis to maintain T4 concentrations (Fig. 2, A). At the end of the
study on PD22, amitrole had caused a pronounced reduction in T4
concentrations at both 25 and 50 mg/kg bw/day, whereas exposure
to the lower dose of MBI (10 mg/kg) and both doses of cyanamide
(Fig. 2, B) left T4 and T3 concentrations unchanged. Dam thyroid
gland mean weights were increased after dosing with 10 mg/kg
Table 2
















Time-mated females (no.) (viable
litters)
4(4) 4(4) 4(0) 4(4) 4(4) 4(4) 4(4)
Pregnant, but could not give birth
and were killed
0 0 4 0 0 0 0
Maternal bw GD7 (g) 245.5 ± 28.2 253.4 ± 36.3 247.9 ± 19.2 242.6 ± 12.3 250.7 ± 29.0 245.6 ± 12.8 245.3 ± 19.8
Maternal bw gain GD7-GD21 (g) 125.5 ± 14.8 123.4 ± 20.0 94.8 ± 14.3 130.7 ± 14.0 127.6 ± 18.8 120.1 ± 14.6 104.5 ± 20.9
Maternal bw gain GD7- PD1 (g) 38.6 ± 3.1 42.4 ± 8.2 e 42.4 ± 10.3 34.6 ± 6.8 37.7 ± 10.9 36.5 ± 5.7
Maternal bw gain PD1-PD14 (g) 41.3 ± 11.3 45.5 ± 3.7 e 36.3 ± 13.6 49.8 ± 12.4 32.0 ± 12.3 42.5 ± 8.5
Maternal bw gain PD14-PD22 29.3 ± 7.5 19.5 ± 1.3 e 9.3 ± 14.2 19.3 ± 8.2 24.5 ± 11.7 19.0 ± 14.5
Gestational length (d) 23 ± 0 23.5 ± 0** e 23 ± 0 23 ± 0 23 ± 0 23 ± 0
Litter size (no.) 14.0 ± 1.4 12.0 ± 2.8 e 14.0 ± 2.2 14.5 ± 2.9 14.8 ± 1.3 13.8 ± 4.0
Litter size. live pups. PD 1 (no.) 14.0 ± 1.4 11.0 ± 2.4 e 14.0 ± 2.2 14.3 ± 2.5 14.5 ± 1.3 13.8 ± 4.0
Postimplantation loss (prenatal
mortality) (%)
5.2 ± 6.8 11.7 ± 10.0 100.0 ± 0.0* 0.0 ± 0.0 1.6 ± 3.6 5.9 ± 6.8 11.3 ± 18.4
Perinatal loss (pre- and postnatal
mortality) (%)
5.2 ± 6.8 18.3 ± 12.6 100.0 ± 0.0* 4.5 ± 9.1 4.3 ± 5.4 11.8 ± 14.4 11.3 ± 18.4
Dam organs
Dam bw PD22 (g) 296.0 ± 20.9 321.8 ± 36.5 e 312.0 ± 23.1 315.8 ± 38.6 290.8 ± 11.8 295.3 ± 34.7
Dam liver weight PD22 (g) 13.7 ± 0.8 14.5 ± 2.3 e 13.9 ± 2.7 15.8 ± 3.7 13.5 ± 0.4 14.1 ± 2.5
Offspring body weight
Birth weight. Male pups (g) 7.2 ± 0.3 7.2 ± 0.3 e 7.5 ± 0.4 7.2 ± 0.4 7.3 ± 0.5 7.0 ± 0.7
Birth weight. Female pups (g) 6.9 ± 0.1 6.8 ± 0.4 e 6.9 ± 0.3 6.9 ± 0.4 6.8 ± 0.5 6.5 ± 0.5
Body weight. PD 6. Male pups (g) 15.0 ± 0.6 14.0 ± 1.7 e 13.3 ± 1.4 13.8 ± 1.3 13.7 ± 1.5 14.0 ± 2.0
Body weight. PD 6. Female pups
(g)
14.1 ± 1.1 13.5 ± 1.9 e 12.5 ± 0.7 13.0 ± 1.1 13.1 ± 1.7 13.4 ± 1.8
Body weight. PD 14. Male pups (g) 39.9 ± 1.2 34.7 ± 4.0 e 29.3 ± 2.8** 30.7 ± 1.7* 31.6 ± 5.3* 31.3 ± 6.0*
Body weight. PD 14. Female pups
(g)
37.7 ± 4.1 33.6 ± 3.6 e 29.0 ± 1.8 30.4 ± 1.8 30.2 ± 5.8 30.8 ± 5.8
Body weight. PD 22. Male pups (g) 73.9 ± 2.1 65.0 ± 0.0a e 54.6 ± 5.4** 56.0 ± 3.4** 57.0 ± 7.1* 52.4 ± 4.0**
Body weight. PD 22. Female pups
(g)
72.9 ± 3.6 65.0 ± 6.7 e 54.0 ± 2.9** 55.6 ± 4.5* 57.6 ± 9.4* 56.3 ± 8.9*
Offspring organ weights
Male pup weight PD16 (g)b 45.7 ± 2.4 38.6 ± 4.6* - 32.7 ± 2.7** 34.9 ± 1.5** 35.2 ± 6.0** 35.2 ± 6.8**
Male pup liver weight PD16 (g)c 1.38 ± 0.11 1.14 ± 0.18 e 0.88 ± 0.06 0.94 ± 0.06 0.98 ± 0.22 0.99 ± 0.20
Male pup thyroid weight PD16
(mg)c
3.6 ± 0.4 4.2 ± 1.6 e 5.0 ± 1.7** 5.8 ± 1.7** 2.8 ± 1.0 2.4 ± 1.2
Bw: body weight. Data shown as litter means ± standard deviation.
*p < 0.05, **p < 0.01 compared to the control. For organ weights body weight was included as covariate in the statistical analysis.
a On PD22 a single litter had remaining male pups.
b Weight of the pups from which the liver weights were obtained.
c Data from two pups per litter and accounting for litter effects in the statistical analysis.
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considerable variations between dams and theweight increases did
not reach statistical significance. Cyanamide did not cause signifi-
cant changes to thyroid hormone concentrations, TSH or thyroid
gland weights in rat dams.
In summary, our study demonstrated clear thyroid hormone
system disruption at both doses of amitrole. There were indications
of thyroid hormone system-disrupting effects in MBI-exposed
dams, most pronounced on GD15 in dams that received the high
dose, but these dams did not survive giving birth. In contrast, there
were no signs of thyroid system disrupting effects in pregnant rats
at highest tested dose of 15/11.25 mg/kg cyanamide, and higher
doses could not be used due to maternal toxicity.
3.4. Thyroid hormone system disruption in offspring
On PD6 and PD16 we assayed T4 serum concentrations in the
pups (Fig. 3) and observed effect patterns like those seen in the
dams. On PD6 (the end of the critical window for heterotopia for-
mation (O’Shaughnessy et al., 2019)) and on PD16, amitrole reduced5
serum T4 concentrations (p ¼ 0.0312). On PD16, T3 serum con-
centrations were also suppressed, albeit without a clear dose-
response relationship. These changes were accompanied by a
pronounced activation of the HPT-axis with increased TSH con-
centrations and increased thyroid gland weights in male pups (fe-
males were not tested). Thyroid weights were significantly
increased both in terms of absolute weights with body weight as a
covariate and weights relative to body weight. MBI and cyanamide
did not affect any of these parameters.
3.5. Developmental neurotoxicity in the form of periventricular
heterotopia
We investigated whether maternal exposure to MBI, amitrole
and cyanamide can lead to the formation of periventricular heter-
otopia in offspring. We found large heterotopia in both hemi-
spheres of all PD16 male pups exposed to 50 mg/kg amitrole
(p < 0.0001, Fig. 4). In contrast, heterotopia formation in MBI and
cyanamide exposed animals were similar to the control, consistent
with the lack of effect on T4 concentrations. Curiously, the
Fig. 2. Serum hormone concentrations and thyroid gland weights in dams exposed to MBI, amitrole or cyanamide from GD7-PD22. A) T4, T3 and TSH serum concentrations in
dams on GD15. B) Dam T4 and T3 serum concentrations and thyroid gland weights on PD22. GD: gestational day, NA: not available, PD: postnatal day, T4: thyroxine, T3: 3,30 ,5-tri-
iodothyronine, TSH: thyroid stimulating hormone, LOQ: limit of quantification. n ¼ 4. Data shown as scatter with mean ± SEM. Dotted line shows the mean of the controls. *p < 0.05,
**p < 0.01.
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were statistically significantly (p < 0.01) smaller in male pups, an
effect we consider a chance finding.
4. Discussion
We have shown that exposure to amitrole during pregnancy and
lactation can induce large heterotopia in the brains of 16 day old
male offspring. The periventricular heterotopia consists of errone-
ously migrated neurons and likely arises from fetal and neonatal
thyroid hormone insufficiency. In contrast, MBI and cyanamide did
not induce heterotopia formation in the rat offspring, likely because
pup thyroid hormone concentrations were not reduced by these
two compounds. To our knowledge, this is the first demonstration
of thyroid hormone dependent heterotopia formation by an envi-
ronmental chemical with in vitro TPO-inhibiting properties.
While amitrole did not significantly lower maternal T4 and T3
serum concentrations at GD15, the PD6 pups did show pronounced
effects on serum T4 with reductions of 50% relative to controls
(below the quantification limit of our assay). It is reasonable to
assume that the pups must have experienced a significant drop in
serum T4 during the entire critical brain developmental window
spanning late foetal to early postnatal life (GD19 to PD6)6
(O’Shaughnessy et al., 2018a, 2019), including low T4 in the brains
themselves (O’Shaughnessy et al., 2018b, 2019). Consequently, this
drop must have been sufficient to disrupt neuronal migration, as
evidenced by the formation of periventricular heterotopia; an
irreversible malformation of the brain. For MBI (10 mg/kg) and
cyanamide (15/11.25 mg/kg) we observed no reduction in dam and
pup serum T4 concentrations. The absence of heterotopia forma-
tion in 16-days old pups was therefore not surprising. If anything,
we saw a minor reduction in heterotopia after exposure to cyana-
mide as compared to sporadically present small heterotopia in
control animals. The fact that neither MBI nor cyanamide sup-
pressed serum T4 concentrations in pregnant dams or their
offspring was somewhat unexpected based on their in vitro TPO
inhibitory properties and capacity to disrupt the thyroid hormone
system in vivo. The most likely explanation to these discrepancies
are doses and time to effect. For MBI we only had pups in the lower
dose group (10 mg/kg). Here, MBI increased serum T4 in PD6 pups
but did not cause any other effects on thyroid hormone concen-
trations. At higher exposure doses, MBI appears to affect the thyroid
hormone system in vivo. For instance, at 20 mg/kg MBI we found
signs of activation of the hypothalamic-pituitary-thyroid axis, with
increased TSH concentrations in the dams at GD15. Notably, MBI
obstructed parturition (dystocia) in pregnant rats, with not a single
Fig. 3. Serum hormone concentrations and thyroid gland weights in offspring developmentally exposed to MBI, amitrole or cyanamide from GD7-PD22. A) T4 serum
concentrations in pups on PD6. n ¼ 8: 4 litters each represented by a male and female pup. LOQ with dotted line shows limit of quantification. B-D) T4, T3 and TSH serum
concentration in pups on PD16. n ¼ 8, 4 litters represented by a male sample (serum poled from three male pups) and a female sample (sample pooled from two female pups). E)
Male pup thyroid gland weight on PD16. n ¼ 8: 4 litters each represented by 2 male pups, and litter effects accounted for in the statistical analysis. NA: not available, PD: postnatal
day, T4: thyroxine, T3: 3,3’,5-tri-iodothyronine, TSH: thyroid stimulating hormone, LOQ: limit of quantification (dashed line in A). Data shown as mean þ SEM. Dotted line shows the
mean of the controls. *p < 0.05, **p < 0.01.
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Fig. 4. Heterotopia formation in PD16 male offspring exposed to MBI, amitrole or cyanamide during perinatal development. A) Amitrole caused marked heterotopia for-
mation with a heterotopia in each brain hemisphere of all 4 pups exposed to amitrole. Heterotopia in MBI and cyanamide-exposed animals were similar to the controls. The rostral-
caudal length of one heterotopia in amitrole exposed animals was on average 525 mm. n ¼ 4. Data shown are the mean number of sections with heterotopia in the left or right
hemisphere þSEM. Dotted line shows the mean of the controls.**p < 0.01 compared to control. B) Representative images of heterotopia from each exposure group at two mag-
nifications. Arrowheads indicate heterotopia or its expected periventricular location. Scale bars ¼ 1 mm, applies to all images, the lower row showing insets of the upper row.
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of all the litters. This adverse toxicological effect precluded us from
drawing any conclusions on potential effects on thyroid hormones
and brain development in the offspring at the high dose. In addition
to our report of increased TSH in pregnant rat dams at 20 mg/kg
MBI, thyroid gland weights were increased in pregnant rat dams at
10 and 30 mg/kg (Yamano et al., 1995) but, to our knowledge, no
other studies have examined thyroid hormone concentrations in
pregnant rats exposed toMBI. Still, in adult male rats exposed for 15
days to 25 and 50 mg/kg MBI there were severe thyroid hormone
reductions, with T4 concentrations below 20% of controls and TSH
increased by approximately 10-fold (Kawasaki et al., 1998). Two
further studies reported hyperplasia/hypertrophy of thyroid
follicular cells at 1.2 mg/kg and enlarged thyroid glands from 4 mg/
kg after repeated exposure (ECHA, 2021a). Taken together, the TPO
inhibiting properties of MBI appear strong enough to cause thyroid
hormone system disruption in vivo (and to a degree that could
affect brain development) but only at doses that cause toxicity in
pregnant rat dams. For cyanamide we did not see any effects on
thyroid hormone concentrations in pregnant dams and their
offspring up to the dose of 15/11.25 mg/kg. As was the case for MBI,
the cyanamide dose of 15/11.25 mg/kg represented the highest
possible exposure dose for pregnant rats, as higher doses will
induce severe toxic responses. However, a few previous studies
show that cyanamide can cause some thyroid hormone system
disruption in vivo. A single developmental study has examined
thyroid-related effects of cyanamide; a two-generation reproduc-
tive toxicity study administered cyanamide in the drinking water at
doses of 0, 20, 60 and 180 ppm to Wistar rats (ECHA, 2021b). At
180 ppm, there was increased thyroid gland weight and thyroid
histopathological changes in the parental generation suggesting
the HPT-axis had been activated. Thyroid histopathological effects
have also been reported in repeated dose toxicity studies in adult
animals exposed to cyanamide (ECHA, 2021b; National Cancer
Institute, 1979), but only two studies measured thyroid hormone
concentrations. These two studies were of very long duration, a 1-
year study in dogs that found T4 concentrations decreased at 5 mg/
kg bw/day, and a chronic toxicity study in rats that found decreased
T3 in females from 2.5 mg/kg bw/day and above and decreased
male T4 at 7.5 mg/kg bw/day (ECHA, 2021b). Thus, as with MBI,
there are in vivo data supporting the view that cyanamide is a
thyroid hormone system-disrupting chemical. In fact, cyanamide
received a STOT-RE Category 2 classification (presumed toxic to
humans following repeated exposure on the basis of evidence from8
studies in experimental animals) for thyroid effects (ECHA, 2021c).
However, available data also indicate that thyroid hormone system
disrupting effects probably occur mainly at higher doses and at
longer exposure times. Based on our data, we surmise that the
toxicological properties of cyanamide make it nearly impossible to
administer doses to pregnant rats that are sufficiently high to cause
thyroid hormone system disruption.
As discussed, MBI, amitrole and cyanamide all appear to reduce
thyroid hormone concentrations in vivo. This is likely through their
TPO-inhibitory properties. Notably, amitrole caused in vivo thyroid
hormone system disruption and adverse effects on brain develop-
ment through relatively weak TPOeinhibitory properties as shown
in Table 1. The only other compounds so far proven to cause het-
erotopia are PTU and MMI, both clinically used drugs, with lower
IC50 and higher efficacy in their TPO inhibition (Table 1). However,
the environmental chemical amitrole with coincidental TPO-
inhibiting capacity turned out to also reduce serum T4 concentra-
tions in rat pups to a degree producing heterotopia in the brain. At
the same time, MBI and cyanamide have more potent in vitro TPO-
inhibitory properties than amitrole, but do not reduce T4 concen-
trations in dams and pups in our experimental setup. This appears
paradoxical but can likely be explained by dosing and chemical
specific toxicokinetics (i.e. absorption, distribution, metabolism
and excretion parameters. This includes the placental and lacta-
tional transfer of compound to foetuses and pups which is all
important for effects in the thyroid hormone system). However a
full elucidation of the relationship between administered dose of
compound, actual internal exposure, and in vivo reductions in T4
over the course of development, would require in-depth tox-
icokinetic investigations and T4 measurements in foetuses and in
pups at several time points; investigations that were out of scope
for this study, but which will be pursued in future investigations of
amitrole.
It is already established that the pesticide amitrole can affect
thyroid hormone concentrations and induce effects on the thyroid
gland (Alexander, 1959; ECHA, 2021d; Stringer et al., 1981). The fact
that amitrole can affect foetal and neonatal thyroid hormone con-
centrations and impact brain development is new knowledge that
is of serious concern. In fact, our study is the first to report any
developmental neurotoxic effects by amitrole, a pesticide that since
2016 is no longer approved for use in the EU (European
Commission, 2021), but is still registered under REACH and used
at 10e1000 tons per year. Of concern, it is found in groundwater
samples (Ministry of Environment and Food of Denmark, 2020).
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potential effects on brain development caused by amitrole and
other thyroid hormone system disrupting chemicals. It also high-
lights inadequacy of regulatory testing requirements and un-
derscores the need for new and more sensitive methods that can
detect effects on brain development after developmental thyroid
hormone system disruption.
Our study was specifically designed to test if environmental
chemicals could cause heterotopia in rats after developmental
exposure to TPO inhibitors. However, our results also revealed that
both MBI and cyanamide can cause reproductive toxicity effects.
MBI had only been investigated in a single teratogenicity study
where pregnant dam and foetuses were examined after MBI-
exposure from GD7-17. MBI reduced foetal weights, foetal visceral
variations and delayed ossification, resulting in a classification for
developmental effects (rep cat 1) (ECHA, 2021a; Yamano et al.,
1995). We now show that adverse reproductive toxicity effects of
MBI also include increased gestation length at 10 mg/kg bw/day
and dystocia with total litter loss at a dose of 20 mg/kg bw/day
administered GD7e22. This effect pattern of prolonged gestation
and disrupted parturition is one MBI shares with many other azole
fungicides. The fungicides interfere with cytochrome P450 en-
zymes of the steroidogenesis pathway (Draskau et al., 2019;
Kjærstad et al., 2010; Osawa et al., 1987; Taxvig et al., 2008; Zhang
et al., 2002) and cause sustained increases in serum progesterone
concentrations, ultimately preventing the pronounced drop in
serum progesterone that is necessary for parturition (Taxvig et al.,
2007; Zakar and Hertelendy, 2007). Parturition was not affected
in the cyanamide-exposed animals, but dam weight gain during
gestation was reduced and indicates that 11.25 mg/kg cyanamide
can be considered a threshold for maternal toxicity in SD rats in
reproductive toxicology studies. Although the REACH registration
dossier for cyanamide (ECHA, 2021b) contains several reproductive
and developmental toxicity studies that investigated doses up to
45 mg/kg and reported severe maternal toxicity it was unexpected
that we found excessive toxicity also at 15 mg/kg.5. Conclusions
We have shown that amitrole is a developmental thyroid hor-
mone system disruptor that can adversely affect brain develop-
ment, manifesting as heterotopia in rat offspring. Amitrole has
coincidental TPO-inhibiting properties that are much weaker than
drugs such as PTU and MMI. Yet, it reduces T4 serum concentra-
tions in both dams and their offspring, likely causing the periven-
tricular heterotopia found in PD16 male pups. Thus, we show that
current testing regimens are not sensitive enough to identify
developmental neurotoxicity through thyroid hormone system
disruption and that heterotopia formation could be used as an
endpoint in regulatory toxicity testing, as demonstrated here for
the TPO-inhibiting pesticide amitrole. Future studies need to
further quantify the relationship between serum and brain T4
concentrations during the critical window, heterotopia formation
and the underlying mechanism.Author statements
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